ClinicalTrials.gg
CompletedNCT00621192Updated Apr 25, 2023Results posted

Pharmacokinetic (PK) and Safety Study of Meropenem in Young Infants With Intra-abdominal Infections

A Phase 1/2 interventional study of meropenem in Necrotizing Enterocolitis and Intra-abdominal Infection, sponsored by The Emmes Company, LLC. Completed at 26 sites in United States. Open to participants aged Up to 90 Days. Per ClinicalTrials.gov, last updated 2023-04-25.

Sponsored by The Emmes Company, LLC · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
Up to 90 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 62 studies in Enterocolitis, Necrotizing with a site in United States — 5 open to participants now, 8 under way, 1 of them phase 3. Enterocolitis, Necrotizing · United States.

Enrollment
7th of 36
200 · median 79
Started
2008
with 3 others
Phase 1/2
4 of 62
1 open now
Registered
12th of 62
by date

Among the 62 studies in Enterocolitis, Necrotizing with a site in United States, this one is the 7th largest by enrollment of the 36 interventional ones that give a count, is one of 4 that started in 2008, is one of 4 in phase 1/2, and was the 12th registered.

Enterocolitis, Necrotizing

229 studies on the registry are indexed under Enterocolitis, Necrotizing; 45 are open to participants now.

Browse Enterocolitis, Necrotizing studies →

Open to participants now

5 of the 62 studies in Enterocolitis, Necrotizing with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Enterocolitis, Necrotizing studies recruiting now, 4 (15%) set no upper age limit and 22 (85%) stop at 75 or younger; 26 take children under 18; 3 take healthy volunteers.

This study: Up to 90 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Enterocolitis, Necrotizing with a site in United States, or all of them as a file.
02

Study summary

Meropenem is an antibiotic that is commonly used to treat serious infections. Although it is used in premature and young infants, the correct dose is not known. The purpose of this study is to determine the correct dose and the safety of meropenem for the treatment of complicated intra-abdominal infections in these young babies.

Read the detailed description

This study will evaluate the safety, tolerability and Pharmacokinetics - Pharmacodynamics (PK-PD) of meropenem in infants \<91 days of age with suspected and complicated intra-abdominal infections.

The specific aims of this trial are:

  1. To characterize meropenem single-dose and multiple-dose PK in subjects with suspected and complicated intra-abdominal infections.
  2. To characterize the safety profile of meropenem in the treatment of suspected and complicated intra-abdominal infections.
  3. To assess collected efficacy data for meropenem for the treatment of suspected and complicated intra-abdominal infections.
03

Conditions studied

  • Necrotizing Enterocolitis
  • Intra-abdominal Infection

Keywords

  • meropenem
  • infants
  • intra-abdominal infection
  • pharmacokinetics
  • safety
04

Who can participate

Ages eligible
Up to 90 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written permission from parent or legal guardian
  2. Age younger than 91 days
  3. Likely to survive beyond the first 48 hours after enrollment
  4. Sufficient intravascular access (either peripheral or central) to receive study drug.

    AND ONE OF THE FOLLOWING

    1. Physical, radiological, and/or bacteriological findings of a complicated intra-abdominal infection. These include peritonitis, NEC (Necrotizing Enterocolitis) Grade II or higher by Bell's criteria, Hirschsprung's disease with perforation, spontaneous perforation, meconium ileus with perforation, bowel obstruction with perforation, as evidenced by free peritoneal air on abdominal radiograph, intestinal pneumatosis or portal venous gas on abdominal radiographic examination.

OR 2) Possible NEC OR 3) Otherwise receiving meropenem per local standard of care

Exclusion criteria

Exclusion criteria:

  1. Renal dysfunction evidenced by urine output \<0.5 mL/hr/kg over the prior 24 hours
  2. Serum creatinine >1.7 mg/dL
  3. History of clinical seizures or EEG (Electroencephalogram) confirmed seizures
  4. Concomitant treatment with another carbapenem (ertapenem or imipenem) at the time of
  5. Any condition which would make the subject or the caregiver, in the opinion of the investigator, unsuitable for the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Meropenem

    These Participants were subdivided into the following four groups based on Gestational Age (GA) and Postnatal Age (PNA): Group 1: GA at birth below 32 weeks - PNA \<2 weeks; Group 2: GA at birth below 32 weeks - PNA ≥2 weeks and \<91 days; Group 3: GA at birth 32 weeks or older - PNA \<2 weeks; Group 4: GA at birth 32 weeks or older - PNA ≥2 weeks and \<91 days.

    Drug: meropenem

Interventions

  • Meropenem was administered concomitantly with compatible medications. Because an in-line filter is not appropriate due to drug binding, the 30 minute infusion was rate controlled by using appropriate infusion (syringe) pumps. Dosing and administration of other antimicrobial therapy (e.g., an aminoglycoside) was administered per local standard of care at the discretion of the infant's neonatologist. If there was a delay in the study drug shipment, sites were to use open-label meropenem to protect the safety of the participant. 20 mg/kg every 12 hours in infants \<32 weeks GA and PNA \< 2 weeks 20 mg/kg every 8 hours in infants \<32 weeks GA and PNA ≥ 2 weeks 20 mg/kg every 8 hours in infants ≥32 weeks GA and PNA \< 2 weeks 30 mg/kg every 8 hours in infants ≥32 weeks GA and PNA ≥ 2 weeks

    Also known as: Merrem

06

What researchers measure

Primary outcomes

  1. Efficacy Success (Alive at Efficacy Visit,Last Culture (if Obtained) From Sterile Body Fluid is Negative for Bacteria (Except Staphylococcus Species) From Start of Study Drug Until Efficacy Visit,Presumptive Clinical Cure Score(PCCS) >7 at Efficacy Visit)

    The PCCS was derived by comparing clinical signs and symptoms prior to administration of the first dose of study drug and study Day 28.The elements of the PCCS include Mean BP,Temp,PaO2(mmHg)/FiO2,Lowest serum pH,seizures,Urine output,Cardiovascular inotrope support,C-reactive protein (CRP)and Abdominal girth. Score - Asymptomatic to Asymptomatic 1;Asymptomatic to Worsening 0;Symptomatic to Worsening 0;Symptomatic to No change 0;Symptomatic to Improved 1;Symptomatic to Asymptomatic 1 If 7 or more of 10 signs received a score of 1, then the infant was considered a presumptive clinical cure. GA stands for Gestational Age and PNA stands for Postnatal Age.

    Time frame: Average of 12 days (3 to 21 days)

  2. Deaths

    Time frame: Up to 51 days (Recorded from the time of informed consent until 72 hours following the last dose of study drug)

  3. Meropenem Clearance

    Given the limited availability of blood for Pharmacokinetic (PK) assessments in this population a sparse sampling approach was utilized. Subjects were assigned to one of two Dose 1 sample collection schedules, "PK-odd" and "PK-even" based on birth date to ensure collection of PK data throughout the dose interval. In addition, PK samples were collected around approximately the 5th dose. Subjects that did not have Dose 1 PK samples could have steady-state (Dose 5) using the Dose 5 PK collection schedule.

    Time frame: Up to 7-8hrs post drug administration

  4. Key Safety Endpoints

    Safety assessments included death, seizure documentation (including correlation of serum meropenem level and seizures), strictures, perforation, wound dehiscence, short gut, development of extended beta lactamase infection, development of candidiasis, antimicrobial therapy failure

    Time frame: Up to 51 days (Adverse Events (AEs) were recorded from the time of informed consent until 72 hours following the last dose of study drug)

07

Results

Posted Nov 29, 2011

Participant flow

Enrollment Period - June 19, 2008 to October 6, 2009 Locations - Hospitals including University Hospitals Total number of sites - 24 Total number of participants - 200

Participant flow — Overall Study
Milestone1. GA <32 Wks; PNA<2 Wks2. GA <32 Wks; PNA 91days ≥ 2Wks3. GA ≥ 32 Wks; PNA <2 Wks4. GA ≥32 Wks; PNA 91 Days ≥ 2 Wks
Started391033127
Safety population391033127
Efficacy population391012827
Completed35942624
Not completed4953
Withdrew: Withdrawal by subject0020
Withdrew: Physician decision1300
Withdrew: Protocol violation1001
Withdrew: Adverse event0101
Withdrew: Death2500
Withdrew: Final assessments not completed0031

Outcome measures

PrimaryEfficacy Success (Alive at Efficacy Visit,Last Culture (if Obtained) From Sterile Body Fluid is Negative for Bacteria (Except Staphylococcus Species) From Start of Study Drug Until Efficacy Visit,Presumptive Clinical Cure Score(PCCS) >7 at Efficacy Visit)

The PCCS was derived by comparing clinical signs and symptoms prior to administration of the first dose of study drug and study Day 28.The elements of the PCCS include Mean BP,Temp,PaO2(mmHg)/FiO2,Lowest serum pH,seizures,Urine output,Cardiovascular inotrope support,C-reactive protein (CRP)and Abdominal girth. Score - Asymptomatic to Asymptomatic 1;Asymptomatic to Worsening 0;Symptomatic to Worsening 0;Symptomatic to No change 0;Symptomatic to Improved 1;Symptomatic to Asymptomatic 1 If 7 or more of 10 signs received a score of 1, then the infant was considered a presumptive clinical cure. GA stands for Gestational Age and PNA stands for Postnatal Age.

Time frame:
Average of 12 days (3 to 21 days)
Reported as:
Number · Participants
Efficacy Success (Alive at Efficacy Visit,Last Culture (if Obtained) From Sterile Body Fluid is Negative for Bacteria (Except Staphylococcus Species) From Start of Study Drug Until Efficacy Visit,Presumptive Clinical Cure Score(PCCS) >7 at Efficacy Visit)
Participants1. GA <32 Wks; PNA<2 Wks2. GA <32 Wks; PNA 91days ≥ 2Wks3. GA ≥ 32 Wks; PNA <2 Wks4. GA ≥32 Wks; PNA 91 Days ≥ 2 Wks
Efficacy Success (Alive at Efficacy Visit,Last Culture (if Obtained) From Sterile Body Fluid is Negative for Bacteria (Except Staphylococcus Species) From Start of Study Drug Until Efficacy Visit,Presumptive Clinical Cure Score(PCCS) >7 at Efficacy Visit)29822625
PrimaryDeaths
Time frame:
Up to 51 days (Recorded from the time of informed consent until 72 hours following the last dose of study drug)
Reported as:
Number · Participants
Deaths
Participants1. GA <32 Wks; PNA<2 Wks2. GA <32 Wks; PNA 91days ≥ 2Wks3. GA ≥ 32 Wks; PNA <2 Wks4. GA ≥32 Wks; PNA 91 Days ≥ 2 Wks
Deaths3800
PrimaryMeropenem Clearance

Given the limited availability of blood for Pharmacokinetic (PK) assessments in this population a sparse sampling approach was utilized. Subjects were assigned to one of two Dose 1 sample collection schedules, "PK-odd" and "PK-even" based on birth date to ensure collection of PK data throughout the dose interval. In addition, PK samples were collected around approximately the 5th dose. Subjects that did not have Dose 1 PK samples could have steady-state (Dose 5) using the Dose 5 PK collection schedule.

Time frame:
Up to 7-8hrs post drug administration
Reported as:
Mean · L/h/kg
Meropenem Clearance
L/h/kg1. GA <32 Wks; PNA<2 Wks2. GA <32 Wks; PNA 91days ≥ 2Wks3. GA ≥ 32 Wks; PNA <2 Wks4. GA ≥32 Wks; PNA 91 Days ≥ 2 Wks
Meropenem Clearance0.089 ± 0.0270.122 ± 0.0370.135 ± 0.0400.202 ± 0.061
PrimaryKey Safety Endpoints

Safety assessments included death, seizure documentation (including correlation of serum meropenem level and seizures), strictures, perforation, wound dehiscence, short gut, development of extended beta lactamase infection, development of candidiasis, antimicrobial therapy failure

Time frame:
Up to 51 days (Adverse Events (AEs) were recorded from the time of informed consent until 72 hours following the last dose of study drug)
Reported as:
Number · Participants
Key Safety Endpoints
Participants1. GA <32 Wks; PNA<2 Wks2. GA <32 Wks; PNA 91days ≥ 2Wks3. GA ≥ 32 Wks; PNA <2 Wks4. GA ≥32 Wks; PNA 91 Days ≥ 2 Wks
Death3 (1.6% to 20.9%)800
Seizure4312
Strictures0000
Perforation2200
Wound Dehiscence1111
Development of Candidiasis5300
Antimicrobial Therapy Failure71222

Adverse events

Collected over Adverse Events (AEs) were recorded from the time of informed consent until 72 hours following the last dose of study drug for non-Serious Adverse Events (SAEs) and until 30 days after the last dose of study drug for SAEs.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1. GA <32 Wks; PNA<2 Wks—9/39 (23.1%)9/39 (23.1%)
2. GA <32 Wks; PNA 91days ≥ 2Wks—18/103 (17.5%)8/103 (7.8%)
3. GA ≥ 32 Wks; PNA <2 Wks—2/31 (6.5%)2/31 (6.5%)
4. GA ≥32 Wks; PNA 91 Days ≥ 2 Wks—5/27 (18.5%)3/27 (11.1%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
Event1. GA <32 Wks; PNA<2 Wks2. GA <32 Wks; PNA 91days ≥ 2Wks3. GA ≥ 32 Wks; PNA <2 Wks4. GA ≥32 Wks; PNA 91 Days ≥ 2 Wks
Intestinal perforationGastrointestinal disorders2/392/1030/310/27
Necrotising ColitisGastrointestinal disorders2/391/1030/310/27
Multi-organ failureGeneral disorders2/392/1030/310/27
Patent Ductus ArteriosusCongenital, familial and genetic disorders0/390/1030/311/27
Intestinal ObstructionGastrointestinal disorders0/390/1030/311/27
Intestinal StenosisGastrointestinal disorders0/390/1030/311/27
Chest X-Ray AbnormalInvestigations0/390/1030/311/27
Pneumonia AspirationRespiratory, thoracic and mediastinal disorders0/390/1030/311/27
Respiratory DistressRespiratory, thoracic and mediastinal disorders0/390/1030/311/27
Rectal HaemorrhageGastrointestinal disorders0/390/1031/310/27
Most frequent other events
Most frequent other events
Event1. GA <32 Wks; PNA<2 Wks2. GA <32 Wks; PNA 91days ≥ 2Wks3. GA ≥ 32 Wks; PNA <2 Wks4. GA ≥32 Wks; PNA 91 Days ≥ 2 Wks
SepsisInfections and infestations5/395/1031/311/27
ConvulsionNervous system disorders4/393/1031/312/27

Baseline characteristics

Age, Continuous
Age, Continuous(Days)1. GA <32 Wks; PNA<2 Wks2. GA <32 Wks; PNA 91days ≥ 2Wks3. GA ≥ 32 Wks; PNA <2 Wks4. GA ≥32 Wks; PNA 91 Days ≥ 2 WksTotal
Mean Postnatal Age8.5 ± 3.338.3 ± 19.36.5 ± 3.536.0 ± 22.027.3 ± 21.6
Sex: Female, Male
Sex: Female, Male(Participants)1. GA <32 Wks; PNA<2 Wks2. GA <32 Wks; PNA 91days ≥ 2Wks3. GA ≥ 32 Wks; PNA <2 Wks4. GA ≥32 Wks; PNA 91 Days ≥ 2 WksTotal
Female154791182
Male24562216118
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)1. GA <32 Wks; PNA<2 Wks2. GA <32 Wks; PNA 91days ≥ 2Wks3. GA ≥ 32 Wks; PNA <2 Wks4. GA ≥32 Wks; PNA 91 Days ≥ 2 WksTotal
Hispanic or Latino5164328
Not Hispanic or Latino32812724164
Unknown or Not Reported26008
Race (NIH/OMB)
Race (NIH/OMB)(Participants)1. GA <32 Wks; PNA<2 Wks2. GA <32 Wks; PNA 91days ≥ 2Wks3. GA ≥ 32 Wks; PNA <2 Wks4. GA ≥32 Wks; PNA 91 Days ≥ 2 WksTotal
American Indian or Alaska Native00000
Asian01012
Native Hawaiian or Other Pacific Islander10102
Black or African American12338558
White25652118129
More than one race12025
Unknown or Not Reported02114
08

Study locations

26 sites
  • University of Alabama
    Birmingham, Alabama 35233, United States
  • Children's Hospital of Oakland
    Oakland, California 94609, United States
  • Children's Hospital of Orange County
    Orange, California 92868, United States
  • University of California Medical Center
    San Diego, California 92117, United States
  • Sharp-Mary Birch Hospital for Women
    San Diego, California 92123, United States
  • Yale New Haven Hospital
    New Haven, Connecticut 06510, United States
  • Children's National Medical Center
    Washington, District of Columbia 20010, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • Kapiolani Medical Center for Women and Children
    Honolulu, Hawaii 96826, United States
  • Evanston Northwestern Healthcare
    Evanston, Illinois 60056, United States
  • Indiana University - Riley Hospital for Children
    Indianapolis, Indiana 46202, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Kansas City Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
  • Albany Medical Center
    Albany, New York 12208, United States
  • Suny Downstate Medical Center
    Brooklyn, New York 11203, United States
  • Duke University Medical Center
    Durham, North Carolina 27708, United States
  • Duke University
    Durham, North Carolina 27715, United States
  • Akron Children's Hospital
    Akron, Ohio 44308, United States
  • Case Western Reserve, RB&C, UHCMC
    Cleveland, Ohio 44106, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Magee Women's Hospital
    Pittsburgh, Pennsylvania 15213, United States
  • Vanderbilt Children's Hospital
    Nashville, Tennessee 37232, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • University of Utah medical Center
    Salt Lake City, Utah 84108, United States
09

References and documents

Publications

  • Cohen-Wolkowiez M, Poindexter B, Bidegain M, Weitkamp JH, Schelonka RL, Randolph DA, Ward RM, Wade K, Valencia G, Burchfield D, Arrieta A, Mehta V, Walsh M, Kantak A, Rasmussen M, Sullivan JE, Finer N, Rich W, Brozanski BS, van den Anker J, Blumer J, Laughon M, Watt KM, Kearns GL, Capparelli EV, Martz K, Berezny K, Benjamin DK Jr, Smith PB; Meropenem Study Team. Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections. Clin Infect Dis. 2012 Dec;55(11):1495-502. doi: 10.1093/cid/cis758. Epub 2012 Sep 5. PubMed 22955430 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2011, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2008
First posted
Feb 22, 2008
Start
Jun 2008
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Results first posted
Nov 29, 2011
Last update
Apr 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00621192
Lead sponsor
The Emmes Company, LLC
Responsible party
Sponsor
First posted
Feb 22, 2008
Start date
Jun 2008
Primary completion
Oct 2009
Completion
Oct 2009
Results posted
Nov 29, 2011
Last update
Apr 25, 2023

Study contacts

Danny Benjamin, MD, PhD, MPH
principal investigator · Duke University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meropenem

Start the discussion